β-tubulin (TUBB)

Overview

β-tubulin is one of the two major protein subunits that assemble into microtubules, the dynamic cytoskeletal polymers essential for cell shape, intracellular transport, mitosis, and chromosome segregation. In biomedical research, β-tubulin is especially important because many anticancer and antiparasitic agents act by binding to tubulin and altering microtubule dynamics, thereby disrupting cell division or parasite viability.

As a drug target, β-tubulin is commonly studied through its role in tubulin polymerization and in ligand binding at sites such as the colchicine binding site. Modulation of β-tubulin can lead to microtubule network disruption, cell-cycle arrest, and apoptosis. Recent studies have also examined α-tubulin and β-tubulin together in the context of microtubule-targeting compounds, including agents combined with epidermal growth factor receptor (EGFR) inhibition, carbonic anhydrase inhibition, Histone deacetylase 6 (HDAC6) modulation, or existing therapies such as Caelyx and paclitaxel.

Recent Publications Summary

Recent studies continued to position β-tubulin as a central target for anticancer drug discovery, with multiple groups designing small molecules to inhibit tubulin polymerization at the colchicine-binding site. Rationally designed imidazo[1,2-a]pyridine, pyrrolo[2,3-b]pyrazine, pyrazolo[4,3-c]pyridine, quinoxaline-chalcone, and triaryl-tethered acryloyl scaffolds were reported to suppress cancer cell growth, disrupt microtubule networks, induce G2/M arrest, and trigger apoptosis in vitro, with several compounds also showing antitumor activity in mouse models without obvious systemic toxicity 42306850Jun41962330Apr41936799Apr42059208Apr41889031Mar. In these studies, lead compounds such as 8o, 10u, 15u, 4i, and 10v were highlighted for potent antiproliferative effects and confirmed inhibition of tubulin polymerization, often supported by docking and molecular dynamics analyses 42306850Jun41962330Apr41936799Apr42059208Apr41889031Mar.

Several publications also explored dual-target strategies in which β-tubulin inhibition was combined with additional mechanisms. A 2-amino-3-cyanopyridine series yielded KMG-732, a dual inhibitor of tubulin polymerization and cyclin G-associated kinase (GAK), with nanomolar to submicromolar cytotoxicity, reduced migration and invasion, favorable pharmacokinetics, minimal P-glycoprotein efflux, and efficacy in organoid and xenograft models 42298883Jun. Another hybrid series of imidazo[1,2-a]quinoxalines targeted both EGFR and tubulin, and compound JRC-6 showed microtubule-stabilizing activity comparable to paclitaxel while also inducing ROS generation, mitochondrial membrane depolarization, and G2/M arrest 42179048May. A coumarin-pyrazolo[1,5-a]pyrimidine series likewise combined carbonic anhydrase IX/XII inhibition with tubulin polymerization blockade, with compound 13n emerging as a balanced dual-target lead 41905101Mar.

Beyond oncology, β-tubulin was also investigated in herbicidal and antiparasitic contexts. A plant-derived lignan, 4-O-α-thevetopyranosyldiphyllin from Taiwania flousiana, was reported to inhibit tubulin polymerization and bind β-tubulin (TUB7) with high affinity in silico, correlating with broad-spectrum pre- and postemergence herbicidal activity and systemic translocation in crops such as rice 42208048May. In a separate anthelmintic study, isolated phytochemicals from Swertia petiolata were docked and simulated against β-tubulin (PDB ID: 1SA0) as part of an integrated in vitro and in silico evaluation against Haemonchus contortus, supporting β-tubulin as a relevant target in parasite control research 41946033Apr.

Additional work extended the β-tubulin-targeting theme to steroid-derived and colchicine-inspired chemotypes. Estratriene analogues based on the 2-methoxyestradiol pharmacophore were synthesized to disrupt microtubules and modulate steroid sulfatase, with several C-17 sulfamoylated compounds showing notable cytotoxicity in HCT-116 and MCF-7 cells 41905481Mar. In parallel, phenoxy-linked colchicine derivatives were designed to enhance selectivity and α-tubulin interaction while retaining the known β-tubulin-binding mode of colchicine; these compounds showed very high antiproliferative potency, favorable selectivity indices, and microtubule disruption in cell-based assays 41797081Mar.

What Changes, What Holds

1. β-tubulin remains a validated anticancer target, with new scaffolds mainly extending the existing microtubule-poisoning playbook
REINFORCES Multiple fresh chemotypes still converge on the same established mechanism: blocking tubulin polymerization at the colchicine site to collapse microtubules, arrest cells in G2/M, and trigger apoptosis 42306850Jun41962330Apr. The added value is breadth and optimization, not a new biological role for β-tubulin. The in vivo activity and low apparent toxicity strengthen druggability, but they do not alter the baseline account of how β-tubulin is being used in cancer discovery.

2. Dual-target designs broaden β-tubulin programs without displacing its core microtubule role
NEW DIRECTION These studies add a second layer to the baseline by pairing β-tubulin inhibition with GAK, EGFR, or carbonic anhydrase blockade, showing that β-tubulin can sit inside multitarget strategies rather than only stand alone 42298883Jun42179048May. That does not contradict the established microtubule-targeting account; it expands how the target is being exploited. The unresolved issue is whether the added targets improve therapeutic windows enough to matter beyond preclinical models.

3. β-tubulin is being used as a herbicidal and antiparasitic target outside oncology
NEW DIRECTION Work in plants and helminths extends the baseline into areas it does not cover, namely weed control and parasite control 42208048May41946033Apr. The established account says β-tubulin is important for cell division and is a drug target in cancer and antiparasitic research, but it does not specifically include herbicidal use. These findings therefore broaden the entity’s practical scope rather than overturning its known microtubule biology.

4. Colchicine-like and steroid-derived chemotypes continue to validate β-tubulin as a microtubule-disrupting scaffold
REINFORCES The new estratriene and phenoxy-linked colchicine analogues stay squarely within the baseline framework: they are designed to disrupt microtubules through β-tubulin engagement and to produce antiproliferative effects 41905481Mar41797081Mar. What changes is medicinal chemistry around the target, not the target’s role itself. The steroid-sulfatase angle is an added feature, but the central message remains that β-tubulin is a productive site for microtubule-directed anticancer design.

Overview update candidates: dual-target β-tubulin strategies; herbicidal use of β-tubulin targeting.